{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"ORR was defined as the number of subjects in a study or treatment group who have a partial response or complete response to the treatment within a certain period of time. A partial response is a decrease in the size of a tumor or in the amount of cancer in the body, and a complete response is the disappearance of all signs of cancer in the body. In a clinical trial, measuring the ORR is one way to see how well a new treatment works.","groups":[{"description":"Cohort 1, Dose Level -1\n\nSubjects will be administered through IV:\n\nPralatrexate 10 mg/m2 on days 1 and 8 of each 21 day cycle.\n\nRomidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.","id":"OG000","title":"Pralatrexate 10 mg/m2, Romidepsin 12 mg/m2"},{"description":"Cohort 2A, Dose Level 1\n\nSubjects will be administered through IV:\n\nPralatrexate 15 mg/m2 on days 1 and 8 of each 21 day cycle.\n\nRomidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.","id":"OG001","title":"Phase 1 Schedule A: Pralatrexate 15 mg/m2, Romidepsin 12 mg/m2"},{"description":"Cohort 2B, Dose Level 1\n\nSubjects will be administered through IV:\n\nPralatrexate 15 mg/m2 on days 1 and 15 of each 28 day cycle.\n\nRomidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.","id":"OG002","title":"Phase 1 Schedule B: Pralatrexate 15 mg/m2, Romidepsin 12 mg/m2"},{"description":"Cohort 3A, Dose Level 2\n\nSubjects will be administered through IV:\n\nPralatrexate 15 mg/m2 on days 1 and 8 of each 21 day cycle.\n\nRomidepsin 14 mg/m2 on days 1 and 8 of each 21 day cycle.","id":"OG003","title":"Phase 1 Schedule A: Pralatrexate 15 mg/m2, Romidepsin 14 mg/m2"},{"description":"Cohort 3B, Dose Level 2\n\nSubjects will be administered through IV:\n\nPralatrexate 15 mg/m2 on days 1 and 15 of each 28 day cycle.\n\nRomidepsin 14 mg/m2 on days 1 and 15 of each 28 day cycle.","id":"OG004","title":"Phase 1 Schedule B: Pralatrexate 15 mg/m2, Romidepsin 14 mg/m2"},{"description":"Cohort 4A, Dose Level 3\n\nSubjects will be administered through IV:\n\nPralatrexate 20 mg/m2 on days 1 and 8 of each 21 day cycle.\n\nRomidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.","id":"OG005","title":"Phase 1 Schedule A: Pralatrexate 20 mg/m2, Romidepsin 12 mg/m2"},{"description":"Cohort 4B, Dose Level 3\n\nSubjects will be administered through IV:\n\nPralatrexate 20 mg/m2 on days 1 and 15 of each 28 day cycle.\n\nRomidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.","id":"OG006","title":"Phase 1 Schedule B: Pralatrexate 20 mg/m2, Romidepsin 12 mg/m2"},{"description":"Cohort 5B, Dose Level 4\n\nSubjects will be administered through IV:\n\nPralatrexate 25 mg/m2 on days 1 and 15 of each 28 day cycle.\n\nRomidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.","id":"OG007","title":"Phase 1 Schedule B: Pralatrexate 25 mg/m2, Romidepsin 12 mg/m2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 1.5 years","title":"Overall Response Rate (ORR) of Subjects Who Received Combination of Pralatrexate and Romidepsin in Phase 1","type":"SECONDARY","unitOfMeasure":"Participants"}